Tonix Pharmaceuticals Expands TONMYA® Commercial Coverage to 52 Million U.S. Lives with Second Payer Deal
TNXP is trading near its 52-week low of $10.87 (5.1% above the low).
Summary
Tonix Pharmaceuticals secured a second commercial payer agreement for its fibromyalgia drug, TONMYA®, adding approximately 17 million U.S. commercial lives. This expands total commercial coverage to about 52 million lives, representing 29% of the U.S. commercial market. This follows the initial agreement announced on May 6, 2026, which covered 35 million lives. Expanding market access is a critical step in commercializing TONMYA, especially given the company's recent 'going concern' warning and increased cash burn reported in its Q1 2026 10-Q. Generating revenue from this product is essential for the company's financial health.
At the time of this announcement, TNXP was trading at $11.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $176.5M. The 52-week trading range was $10.87 to $69.97. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.